This company has been acquired
TCR2 Therapeutics Dividende
Zukünftiges Wachstum Kriterienprüfungen 0/6
TCR2 Therapeutics does not have a record of paying a dividend.
Wichtige Informationen
n/a
Dividendenausschüttung
n/a
Ausschüttungsquote
| Durchschnittlicher Branchenertrag | 2.8% |
| Nächster Dividendenzahlungstermin | n/a |
| Ex-Dividendendatum | n/a |
| Dividende pro Aktie | n/a |
| Gewinn pro Aktie | -US$4.15 |
| Erwartete Dividendenrendite in 3 Jahren | n/a |
Aktuelle Dividendenentwicklung
Keine Aktualisierungen
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08
Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10Stabilität und Wachstum des Zahlungsverkehrs
Rufe Dividendendaten ab
Stabile Dividende: Insufficient data to determine if TCRR's dividends per share have been stable in the past.
Wachsende Dividende: Insufficient data to determine if TCRR's dividend payments have been increasing.
Dividendenrendite im Vergleich zum Markt
| TCR2 Therapeutics Dividendenrendite im Vergleich zum Markt |
|---|
| Segment | Dividendenrendite |
|---|---|
| Unternehmen (TCRR) | n/a |
| Untere 25 % des Marktes (US) | 1.6% |
| Markt Top 25 % (US) | 4.8% |
| Branchendurchschnitt (Biotechs) | 2.8% |
| Analystenprognose in 3 Jahren (TCRR) | n/a |
Bemerkenswerte Dividende: Unable to evaluate TCRR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hohe Dividende: Unable to evaluate TCRR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Gewinnausschüttung an die Aktionäre
Abdeckung der Erträge: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Barausschüttung an die Aktionäre
Cashflow-Deckung: Unable to calculate sustainability of dividends as TCRR has not reported any payouts.